Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

Summary

In this study two MGCD265 oral formulations at dose level of 100 mg are administered to healthy male and female subjects under fasting conditions.

Timeline

Start

2013-08

Primary completion

2013-12

Completion

2013-12

Drugs

Indications